glutathione for myoclonus Depletion and MicroRNA Dysregulation in Multiple System Atrophy: A Review Progressive Myoclonus Epilepsy: A Scoping
Description
PMID 21423166
H.JakobyW
Some individuals may experience nausea even at this initial dose, though it's generally well-tolerated
Next steps: FDA decision (REDEFINE-1 & 2) expected late 2026 REDEFINE-11 (2.4/2.4 mg) readout in H1 2027 Higher-dose Phase 3 initiation planned H2 2026 Why It Matters: The obesity market is now a high-efficacy battleground, with GLP-1 and dual incretin therapies redefining standards of care
